Search results for " ostetricia"

showing 10 items of 315 documents

Hysterectomy using Vaginal Natural Orifice Transluminal Endoscopic surgery (vNOTES) compared with classic laparoscopic hysterectomy: a new advantageo…

2023

Introduction: Minimally invasive surgery aims to reduce surgical trauma and postoperative morbidity. Natural orifice transluminal endoscopic surgery (NOTES) is a safe and valid surgical option for hysterectomy. The present systematic review aims to compare hysterectomy by transvaginal natural orifice transluminal endoscopic surgery (vNOTES) with laparoscopic hysterectomy in terms of efficacy, surgical outcomes, complications, and cost. Materials and methods: This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. It includes randomized controlled trials, controlled clinical trials, prospective or retrospec…

NoneSettore MED/40 - Ginecologia E Ostetricia
researchProduct

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

2014

Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse recei…

OVARIAN CANEROrganoplatinum Compoundsmedicine.medical_treatmentdrug therapy/pathology/surgery/therapyCarcinoma Ovarian EpithelialMultimodal ImagingCohort StudiesObstetrics and gynaecologyNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsInfusions ParenteralNeoplasms Glandular and EpithelialLaparoscopyadministration /&/ dosageTomographyRandomized Controlled Trials as TopicOvarian Neoplasmsmedicine.diagnostic_testObstetrics and GynecologyGlandular and EpithelialMiddle AgedDebulkingCombined Modality TherapyIsolated platinum sensitive relapseX-Ray ComputedOxaliplatinPhase III as TopicOncologyFemalediagnostic usemedicine.drugmedicine.medical_specialtyInfusionsAged Antineoplastic Combined Chemotherapy Protocols; administration /&/ dosage Cisplatin; administration /&/ dosage Clinical Trials; Phase II as Topic Clinical Trials; Phase III as Topic Cohort Studies Combined Modality Therapy Female Fluorodeoxyglucose F18; diagnostic use Humans Hyperthermia; Induced; methods Infusions; Parenteral Middle Aged Minimally Invasive Surgical Procedures Multimodal Imaging Neoplasms; Glandular and Epithelial; drug therapy/pathology/surgery/therapy Organoplatinum Compounds; administration /&/ dosage Ovarian Neoplasms; drug therapy/pathology/surgery/therapy Positron-Emission Tomography Radiopharmaceuticals; diagnostic use Randomized Controlled Trials as Topic Retrospective Studies Tomography; X-Ray Computed ocal; pathologyocalmethodsClinical Trials Phase II as TopicMinimally invasive surgeryOvarian cancerFluorodeoxyglucose F18ParenteralmedicineHumansMinimally Invasive Surgical ProceduresClinical TrialsHyperthermiaAgedRetrospective StudiesCisplatinChemotherapySeries (stratigraphy)HIPECbusiness.industryPhase II as TopicInducedHyperthermia Inducedmedicine.diseaseOxaliplatinSurgeryRoboticSettore MED/40 - GINECOLOGIA E OSTETRICIAClinical Trials Phase III as TopicPositron-Emission TomographyLaparoscopypathologyNeoplasm Recurrence LocalCisplatinRadiopharmaceuticalsbusinessOvarian cancerTomography X-Ray Computed
researchProduct

Robotic versus laparoscopic surgery in gynecology: Which should we use?

2015

This review of the literature aims at assessing the safety and effectiveness of robotic versus laparoscopic surgery in benign and malignant gynecological diseases. Robotic-assisted laparoscopy is already widely used in the United States and Europe for the main gynecological procedure - hysterectomy - and has proved feasible and comfortable for other benign and malignant gynecological procedures. However, the clinical effectiveness and safety of robotic surgery compared with standard laparoscopy have not been undoubtedly established. We reviewed the literature by searching in the Ovid/MEDLINE, PubMed, Cochrane Library, and Google Scholar databases for all the articles published from January …

Obstetrics and GynecologyRobotic surgical procedureHysterectomyGynecologic Surgical ProceduresSettore MED/40 - GINECOLOGIA E OSTETRICIAMinimally invasive surgical proceduresHumansFemaleHysterectomy; Laparoscopy; Minimally invasive surgical procedures; Robotic surgical procedures; Obstetrics and GynecologyLaparoscopyRobotic surgical proceduresGenital Diseases FemaleMinimally invasive surgical procedure
researchProduct

Women's Health and Gynecology: Old Challenges and New Insights.

2022

The complexity of women’s health goes far beyond medical and surgical knowledge and the achievements of the clinical specialty of Obstetrics and Gynecology, spanning not just the research dimensions of molecular biology, genetics, epidemiology, or health services but also being influenced by gender, social, and psychological relevant factors [...]

ObstetricsGynecologyHealth Toxicology and MutagenesisPublic Health Environmental and Occupational HealthHumansWomen's HealthFemaleSettore MED/40 - Ginecologia E OstetriciaInternational journal of environmental research and public health
researchProduct

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MIT…

2011

Purpose Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy. Patients and Methods Chemotherapy-naive patients with stage IC to IV ovarian cancer (age ≤ 75 years; Eastern Cooperative Oncology Group performance status ≤ 2) were randomly assigned to carboplatin area under the curve (AUC) 5 plus paclitaxel 175 mg/m2 or to carboplatin AUC 5 plus PLD 30 mg/m2, every 3 weeks for six cycles. Primary end point was progression-free survival (…

OncologyAdultCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsPolyethylene GlycolDisease-Free Survivallaw.inventionCarboplatinPolyethylene GlycolsAntineoplastic Agentchemistry.chemical_compoundRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansDoxorubicinAgedOvarian NeoplasmsChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryOvarian NeoplasmArea under the curveCancerMiddle Agedmedicine.diseaseCarboplatinSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAOncologychemistryPaclitaxelDoxorubicinQuality of LifeFemalebusinessOvarian cancerHumanmedicine.drug
researchProduct

Clinical outcome of recurrent locally advanced cervical cancer (LACC) submitted to primary multimodality therapies

2015

Abstract Objectives Recurrence of disease represents a clinical challenge in cervical cancer patients, especially when all available treatment modalities have been used in the primary setting. The aim of this study was to analyze the patterns of recurrence and their association with clinical outcome in locally advanced cervical cancer (LACC) patients submitted to primary chemoradiation (CTRT) followed by radical surgery (RS). Methods This study was conducted on 364 LACC patients treated with CTRT plus RS since January 1996 to July 2012. For each relapse, information on date of clinical/pathological recurrence, and pattern of disease presentation were retrieved. Post-relapse survival (PRS) w…

OncologyAdultmedicine.medical_specialtyUterine Cervical Neoplasmrecurrent cervical cancerPrognosimedicine.medical_treatmentUterine Cervical NeoplasmsDiseaseObstetrics and gynaecologyRetrospective StudieInternal medicinemedicineHumansRadical surgeryChemoradiation; Post-relapse survival; Prognosis; Radical hysterectomy; Recurrent cervical cancer; Adult; Chemoradiotherapy; Adjuvant; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence; Local; Retrospective Studies; Survival Analysis; Treatment Outcome; Uterine Cervical NeoplasmschemoradiationSurvival analysisNeoadjuvant therapyAdjuvantRetrospective StudiesSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIACervical cancerbusiness.industrypost-relapse survivalObstetrics and GynecologyRetrospective cohort studyChemoradiotherapy AdjuvantChemoradiotherapymedicine.diseaseSurvival AnalysisNeoadjuvant TherapySurgeryLog-rank testTreatment OutcomeNeoplasm RecurrenceSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyLocalradical hysterectomyFemaleSurvival AnalysiprognosisNeoplasm Recurrence LocalbusinessHuman
researchProduct

Mesenteric Lymph Node Involvement in Advanced Ovarian Cancer Patients Undergoing Rectosigmoid Resection: Prognostic Role and Clinical Considerations

2014

Background: The aim of this retrospective study was to investigate the incidence of mesenteric lymph node (MLN) involvement, and its prognostic role in advanced ovarian cancer (OC). Methods: OC patients undergoing rectosigmoid resection during primary debulking surgery or interval debulking surgery were recorded. Progression-free survival (PFS) and overall survival were calculated from the date of diagnosis to the date of relapse/progression, death of disease, or the date of last follow-up. Results: MLNs were detected in 102/148 cases (68.9 %); the rate of MLN involvement was 47.0 %. The percentage of metastatic MLNs was higher in cases with >5 MLNs removed compared with cases with ≤5 MLNs …

OncologySettore MED/18 - CHIRURGIA GENERALEGastroenterologyClear CellSurgical oncology80 and overMucinousMesenteryCystadenocarcinomaLymph nodeAged 80 and overOvarian NeoplasmsMedicine (all)Middle AgedDebulkingPrognosisAdenocarcinoma MucinousOVARIAN CANCERSurvival Ratemedicine.anatomical_structureOncologyLymphatic MetastasisAdenocarcinomaFemaleAdultmedicine.medical_specialtyCystadenocarcinomaAdenocarcinomaAdenocarcinoma Clear Cell; Adenocarcinoma Mucinous; Adult; Aged; Aged 80 and over; Cystadenocarcinoma Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mesentery; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Prognosis; Rectum; Retrospective Studies; Sigmoid Neoplasms; Survival Rate; Surgery; OncologyInternal medicinemedicineHumansSurvival rateAgedRetrospective Studiesbusiness.industryRectumSerousRetrospective cohort studymedicine.diseaseCystadenocarcinoma SerousEndometrial NeoplasmsSigmoid NeoplasmsSettore MED/40 - GINECOLOGIA E OSTETRICIALymph Node ExcisionSurgeryLymph NodesNeoplasm GradingOvarian cancerbusinessAdenocarcinoma Clear CellFollow-Up Studies
researchProduct

Survival after curative pelvic exenteration for primary or recurrent cervical cancer a retrospective multicentric study of 167 patients

2014

ObjectiveEvaluate the survival of patients who underwent pelvic exenteration (PE) with curative intent for primary persistent or recurrent cervical cancer.MethodsWe retrospectively investigated 167 consecutive patients, referred to the gynecological oncology units of 4 centers in Germany or Italy, who underwent PE. Data regarding surgery, histology, and oncologic outcomes were collected and statistically evaluated. Survival was determined from the day of exenteration until last follow-up or death.ResultsThe median age was 51 years. Twenty-seven patients (16.2%) underwent PE owing to advanced primary tumors (group A), 34 patients (20.4%) underwent PE owing to persistent cancer after chemothe…

OncologyUterine Cervical NeoplasmSurvivalmedicine.medical_treatmentUterine Cervical NeoplasmsRetrospective StudieLymph nodeCervical cancerAged 80 and overMedicine (all)Obstetrics and GynecologyMiddle AgedPrognosisCombined Modality TherapySurvival Ratemedicine.anatomical_structureOncologyLymphatic MetastasisCarcinoma Squamous CellAdenocarcinomaFemaleHumanAdultmedicine.medical_specialtyPrognosiAdenocarcinomaFollow-Up StudieYoung AdultInternal medicinemedicineCarcinomaHumansSurvival pelvic exenteration primary recurrent cervical cancerSurvival rateRetrospective StudiesAgedNeoplasm StagingPelvic exenterationbusiness.industryCancerRetrospective cohort studyLymphatic Metastasimedicine.diseaseSurgeryPelvic ExenterationSettore MED/40 - GINECOLOGIA E OSTETRICIACervical cancerNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

What is the prognostic importance of lymphovascular space invasion in the absence of lymph node metastasis for early-stage endometrial cancer?

2021

Objective: The aim of this study is to analyze the prognostic role of lymph-vascular space invasion (LVSI), evaluated in a semi-quantitative fashion on prognosis of early stage, low risk endometrial cancer (EC). Methods: We enrolled patients who underwent surgery for endometrial cancer between 2003 and 2018 in two referral cancer center. All patients had endometrioid EC, G1–G2, with myometrial invasion <50%, and no lymph-node involvement. LVSI was analyzed in a semi-quantitative way, according to a 3-tiered scoring system in absent, focal and substantial. Results: Among 524 patients, any positive LVSI was found in 57 patients (10.9%) with focal LVSI (n=35, 6.7%) and substantial LVSI (n=2…

Oncologymedicine.medical_specialtyMultivariate analysisLymph node metastasisEndometrial Cancer03 medical and health sciences0302 clinical medicineText miningInternal medicineMedicineHumansRisk factorStage (cooking)Neoplasm MetastasisLetter to the EditorUnivariate analysis030219 obstetrics & reproductive medicineEndometrial Cancer; Neoplasm Metastasis; Prognostic FactorsEndometrial Cancer Neoplasm Metastasis Prognostic Factorsbusiness.industryPrognostic FactorsEndometrial cancerHazard ratioCancerObstetrics and GynecologyGeneral Medicinemedicine.diseasePrognosisLymphovascularEndometrial NeoplasmsSettore MED/40 - GINECOLOGIA E OSTETRICIAOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionFemaleLymphNeoplasm Recurrence LocalbusinessCarcinoma EndometrioidJournal of gynecologic oncology
researchProduct

Role of robotic surgery in ovarian malignancy

2017

As part of minimally invasive surgery, robotic-assisted approach is becoming increasingly popular in gynecologic oncology. It has been shown to be effective and feasible for staging and treating endometrial and cervical cancer, but its role in the context of primary and recurrent ovarian cancers is presently debated. Scanty data are available in the literature, and the level of evidence supporting its use in ovarian cancer is quite low. However, from a retrospective case-control series, robotic surgery seems to be safe and feasible for early-stage ovarian cancer. Its use in treating patients with advanced-stage or relapsed ovarian cancer is still highly controversial, suggesting the choice …

Oncologymedicine.medical_specialtyPopulationContext (language use)robotic surgery ovarian cancerGynecologic oncologygynecologic oncology03 medical and health sciencesGynecologic Surgical Procedures0302 clinical medicineRobotic Surgical ProceduresInternal medicinerobotic surgerymedicineHumansRobotic surgeryeducationOvarian malignancygynecologic oncology; minimally invasive surgery; ovarian cancer; robotic surgery; Obstetrics and Gynecologyminimally invasive surgeryNeoplasm StagingRetrospective StudiesOvarian NeoplasmsCervical cancereducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryGeneral surgeryObstetrics and GynecologyGeneral MedicineEvidence-based medicinemedicine.diseasegynecologic oncology; minimally invasive surgery; ovarian cancer; robotic surgery; Case-Control Studies; Female; Gynecologic Surgical Procedures; Humans; Neoplasm Recurrence Local; Neoplasm Staging; Ovarian Neoplasms; Retrospective Studies; Robotic Surgical Procedures; Treatment OutcomeTreatment Outcomeovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIACase-Control Studies030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessOvarian cancer
researchProduct